Wearable cardioverter defibrillators are used by people who may be at higher risk for sudden cardiac arrest, including those with weakened heart function, awaiting cardiac transplant or with a condition that prevents or delays them from receiving an implanted defibrillator.
The device monitors heart rhythm, emits alarms if a serious arrhythmia occurs, delivers an electric shock to the heart if needed and alerts bystanders to help if the heart's electrical activity has stopped.
About 5,000 patients are using wearable defibrillators at any one time, usually for about 60 days, said Vincent N. Mosesso Jr., M.D., professor of emergency medicine at the University of Pittsburgh School of Medicine and principal investigator of the study.
"In these patients, the wearable defibrillator is a non-invasive 'insurance policy' against sudden arrest during their vulnerable period," he said.
Researchers gathered heart rhythm records and calls about shocks from a registry of 14,475 patients with wearable defibrillators listed from 2007 through 2009. Of those, 185 (about 1 percent) received an appropriate shock and 91.6 percent survived one or more episodes of ventricular fibrillation or ventricular tachycardia, the most common abnormal rhythms during cardiac arrest.
Wearable defibrillators delivered 223 inappropriate shocks to 213 people who weren't experiencing ventricular fibrillation or ventricular tachycardia. However, no one died as a result. Researchers attribute the inappropriate shocks to signal noise, rapid non-VT rhythms, and rhythm misinterpretation.
Only about 7 percent of people in the United States who have sudden cardiac arrest outside the hospital survive to hospital discharge, and only about 21 percent who have them in the hospital survive to discharge.
"This study confirms the effectiveness of very early defibrillation as therapy for sudden cardiac arrest in high-risk patients when delivered by a wearable defibrillator," Mosesso said. "These defibrillators provide patients the critical advantage of not having to wait for a bystander or emergency responder to recognize the cardiac arrest and use an automated external defibrillator or manual defibrillator — both of which can lead to delays in treatment and markedly worse survival rates."
Co-authors are: Jie Li, M.S.; Douglas Landsittel, Ph.D. and Leonard I. Ganz, M.D. Author disclosures are on the abstract.
ZOLL LifeCor of Pittsburgh, which makes the wearable defibrillator used in the study, funded the research.
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.
AHA News Media Office | EurekAlert!
New insight into the brain’s hidden depths: Jena scientists develop minimally-invasive endoscope
27.11.2018 | Leibniz-Institut für Photonische Technologien e. V.
New China and US studies back use of pulse oximeters for assessing blood pressure
21.11.2018 | University of British Columbia
What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...
A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.
Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...
Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...
What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.
Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...
12.12.2018 | Event News
10.12.2018 | Event News
06.12.2018 | Event News
13.12.2018 | Life Sciences
13.12.2018 | Physics and Astronomy
13.12.2018 | Earth Sciences